Compare ICFI & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICFI | AVLN |
|---|---|---|
| Founded | 1969 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2006 | 2026 |
| Metric | ICFI | AVLN |
|---|---|---|
| Price | $85.99 | $32.09 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $99.25 | N/A |
| AVG Volume (30 Days) | 134.8K | ★ 184.1K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.61 | N/A |
| Revenue | ★ $1,229,162,000.00 | N/A |
| Revenue This Year | $4.12 | N/A |
| Revenue Next Year | $5.33 | N/A |
| P/E Ratio | $33.21 | ★ N/A |
| Revenue Growth | ★ 3.72 | N/A |
| 52 Week Low | $58.83 | $24.90 |
| 52 Week High | $98.03 | $40.17 |
| Indicator | ICFI | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 38.65 |
| Support Level | $84.61 | $25.86 |
| Resistance Level | $90.93 | $33.32 |
| Average True Range (ATR) | 2.29 | 2.21 |
| MACD | -0.50 | -0.59 |
| Stochastic Oscillator | 33.42 | 3.40 |
ICF International Inc provides professional services and technology-based solutions, including management, technology and policy consulting and implementation services, to government and commercial clients in the U.S. and internationally. Its government clients include U.S. federal agencies, state and local governments and international governments, as well as commercial clients inside and outside the U.S. It supports clients in Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs; and Security and Other Civilian and Commercial markets. The company delivers services across the life cycle of a policy, program or project through Advisory Services, Program Implementation, Analytics Services, Digital Services and Engagement Services.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.